Short answer. A lot of posts on Oct 29 treated the filing as a switch that flipped every peptide to "legal and proven." The notice did not do that. As of Oct 29, 2026.

Still true the next day

• The six are not FDA-approved. Compounded drugs are not reviewed for safety, effectiveness, or quality before marketing [1].

• None of the six was added to the 503A bulks list. Rulemaking continues, and it may propose adding some or all [1].

• The policy is a draft. It creates no rights and is not binding. HHS may revisit it [1].

• Research-use-only sellers are not the compounders the notice names [1][2].

• Blends are outside the single-ingredient condition [2].

• No dose or calendar was published in the discretion lines. Epitalon's "intermittent courses" is a limit, not a schedule you can copy [2].

• Sermorelin, DSIP, GHK-Cu, CJC-1295, ipamorelin, selank, and the other names people attach to this story are not in Appendix A [2].

• Leaving Category 2 in April did not, in the policy's own words, change 503A status [2].

• CDER's recommendation against listing is still part of the document [2].

• Sommar Club does not prescribe or sell BPC-157, TB-500, MOTS-c, epitalon, semax, or KPV.

What did change

HHS put a draft policy on public inspection on Oct 28, 2026, at 11:15 a.m., and scheduled it for the Federal Register on Oct 30 [1]. In that policy, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician that compounds one of six named forms, by the named routes, when every condition is met [1][2].

That is the change. It is real, and it is narrow. The hub is HHS and 6 peptides: what changed. The conditions are in The ten conditions, in order.

FAQ

So is the group chat wrong? The chat is right that HHS filed something about six peptides. It is wrong if it says those peptides are approved, listed, dosed, or for sale from a research site [1][2].

Where do comments go? regulations.gov, docket HHS-OASH-2026-0496, for two weeks after publication [1].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, including Appendices A and B. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.